Abstract
Background PD is associated with non-motor symptoms appearing before the motor symptoms onset. Recent studies report dysfunctions of visual structures at early stages of PD.
Objective This study addresses effective connectivity in the visual network of PD patients.
Methods Using brain functional MRI and Dynamic Causal Modeling analysis, we investigated the connectivity between the superior colliculus, the lateral geniculate nucleus and the primary visual area V1 in 22 de novo untreated PD patients and six months after starting dopaminergic treatment compared to age-matched healthy controls.
Results Our findings indicate that the superior colliculus drives cerebral activity for luminance contrast processing both in healthy controls and untreated PD patients. The same effective connectivity was observed with neuromodulatory differences in terms of neuronal dynamic interactions. The modulation induced by luminance contrast changes of the superior colliculus connectivity (self-connectivity and connectivity to the lateral geniculate nucleus) was inhibited in PD patients (effect of contrast: p = 0.79 and p = 0.77 respectively). The introduction of dopaminergic medication failed to restore the effective connectivity modulation observed in the healthy controls.
Interpretation The deficits in luminance contrast processing in PD seem due to a deficiency in connectivity adjustment from the superior colliculus to the lateral geniculate nucleus and to V1. Administration of a dopaminergic treatment over six months was not able to normalize the observed alterations in inter-regional coupling. These findings highlight the presence of early dysfunctions in primary visual areas, which might be used as early markers of the disease.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT02488395
Funding Statement
Emmanuelle Bellot is the recipient of a grant from the France Parkinson Foundation and from the University Grenoble Alpes. This work was partly supported by a grant from La Fondation de l Avenir (France). The Grenoble MRI facility IRMaGe was partly funded by the French program Investissement d Avenir run by the Agence Nationale pour la Recherche (ANR-11-INBS-0006).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the local ethical committee (Committee de Protection des Personnes Sud-Est V, ID RCB-2012-A00310-43 and ID RCB-2014-A01835-42) and registered with ClinicalTrial.gov (NCT02488395).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All the data are available on request for scientific research objectives (contact M. Dojat). The data are not publicly available due to privacy restrictions, stated in the document approved by the Institutional Review Board.
Abbreviations
- BOLD
- Bold Oxygen Level Dependent
- DCM
- Dynamic Causal Modelling
- fMRI
- functional Magnetic Resonance Imaging
- LGN
- Lateral Geniculate Nucleus
- PD
- Parkinson’s Disease
- ROI
- Region Of Interest
- SC
- Superior Colliculus
- V1
- primary visual cortex.
